Page 1668 - Hematology_ Basic Principles and Practice ( PDFDrive )

1486 Part VIII Comprehensive Care of Patients with Hematologic Malignancies

12. Sheinfeld Gorin S, et al: Meta-analysis of psychosocial interventions to 39. Smith TJ, et al: Implantable drug delivery systems (IDDS) after failure
reduce pain in patients with cancer. J Clin Oncol 30(5):539–547, 2012. of comprehensive medical management (CMM) can palliate symptoms
13. Montgomery GH, et al: Hypnosis for cancer care: over 200 years young. in the most refractory cancer pain patients. J Palliat Med 8(4):736–742,
CA Cancer J Clin 63(1):31–44, 2013. 2005.
14. Thomas JW, Cohen M: A methodological review of meditation research. 40. Swarm RA, Cousins MJ: Anaesthetic techniques for pain control. In
Front Psychiatry 5:74, 2014. Hanks G, Cherny NI, Christakis NA, et al, editors: Oxford textbook of
15. Sheinfeld Gorin S, et al: Meta-analysis of psychosocial interventions to palliative medicine, ed 3, Oxford, UK, 2010, Oxford University Press,
reduce pain in patients with cancer. J Clin Oncol 30(5):539–547, 2012. p 390.
16. Hurlow A, et al: Transcutaneous electric nerve stimulation (TENS) 41. Portenoy RK: Adjuvant analgesics in pain management. In Hanks G,
for cancer pain in adults. Cochrane Database Syst Rev (3):CD006276, Cherny NI, Christakis NA, et al, editors: Oxford textbook of palliative
2012. medicine, ed 3, Oxford, UK, 2010, Oxford University Press, p 361.
17. Sze WM, Shelley MD, Held I, et al: Palliation of metastatic bone pain: 42. McDonald A, Portenoy RK: How to use antidepressants and anticonvul-
Single fraction versus multifraction radiotherapy—A systematic review sants as adjuvant analgesics in the treatment of neuropathic cancer pain.
of randomized trials. Clin Oncol 15:345, 2003. J Support Oncol 4:43, 2006.
18. Berenson J, Pfugmacher R, Jarzem P, et al: Balloon kyphoplasty versus 43. Filron I, Bailey JM, Tu D, et al: Nortriptyline and gabapentin, alone
non-surgical fracture management for treatment of painful vertebral and in combination for neuropathic pain: A double-blind, randomized
body compression fractures in patients with cancer: A multicentre, controlled crossover trial. Lancet 374(9697):1252, 2009.
randomized controlled trial. Lancet Oncol 12:225, 2011. 44. Kyle RA, Yee GC, Somerfield MR, et al: American Society of Clinical
19. Stearns L, Boortz-Marx R, Du Pen S, et al: Intrathecal drug delivery for Oncology clinical practice guideline update on the role of bisphospho-
the management of cancer pain: A multidisciplinary consensus of best nates in multiple myeloma. J Clin Oncol 25:2464, 2007.
clinical practices. J Support Oncol 3:399, 2005. 45. Hazekamp A, Grotenhermen F: Review on clinical studies with cannabis
20. Miguel R: Interventional treatment of cancer pain: the fourth step and cannabinoids 2005–2009. Cannabinoids 5:1–21, 2010.
in the World Health Organization analgesic ladder? Cancer Control 46. Portenoy RK, et al: Nabiximols for opioid-treated cancer patients with
7(2):149–156, 2000. poorly-controlled chronic pain: A randomized, placebo-controlled,
21. Rawlins MD, et al: Non-opioid analgesics. In Hanks G, Cherny NI, graded-dose trial. J Pain 13:438–449, 2012.
Christakis NA, editors: Oxford textbook of palliative medicine, ed 3, 47. Eliezer S, Fall-Dickson JM, Berger AM: Oral Complications. In DeVita
Oxford, UK, 2010, Oxford University Press, p 355. VT, Lawrence TS, Rosenberg SA, editors: Cancer:principles and practice
22. Joishy SK, Walsh D: The opioid-sparing effects of intravenous ketorolac of oncology, ed 9, Philadelphia, 2011, Wolters Kluwer/Lipincott Williams
as an adjuvant analgesic in cancer pain: Application in bone metastases and Wilkins, p 2337.
and the opioid bowel syndrome. J Pain Symptom Manage 16:334, 1998. 48. Sasse AD, Clark LG, Sasse EC, et al: Amifostine reduces side effects
23. Vascular and upper gastrointestinal effects of non-steroidal anti- and improves complete response rate during radiotherapy: results of a
inflammatory drugs: meta-analyses of individual participant data from meta-analyses. Int J Radiat Oncol Biol Phys 64:784, 2006.
randomised trials. Lancet 382(9894):769–779, 2013. 49. Crawford J, Tomita DK, Mazanet R, et al: Reduction of oral mucositis
24. Trelle S, Reichenbach S, Wandel S, et al: Cardiovascular safety of by filgrastom (rmetHuG-CSF) in patients receiving chemotherapy.
non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ Cytokines Cell Moll Ther 5:187, 1999.
342:c7086, 2011. 50. Innocenti M, Moscatelli G, Lopez S: Efficacy of gelclair in reducing pain
25. McNicol E, et al: NSAIDS or paracetamol, alone or combined with in palliative care patients with oral lesions: preliminary findings from an
opioids, for cancer pain. Cochrane Database Syst Rev (1):CD005180, open pilot study. J Pain Symptom Manage 24:456, 2002.
2005. 51. Moore RA, Wiffen PJ, Derry S, et al: Gabapentin for chronic neu-
26. Swarm RA, Abernethy AP, et al: Adult cancer pain. J Natl Compr Canc ropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev
Netw 11(8):992–1022, 2013. (3):CD007938, 2011.
27. Portenoy RK: Cancer pain management. Clin Adv Hematol Oncol 3:30, 52. Sabatowski R, Galvez R, Cherry DA, et al: Pregabalin reduces pain and
2005. improves sleep and mood disturbances in patients with post-herpetic
28. Zeppetella G, et al: Opioids for the management of breakthrough pain neuralgia: results of a randomized, placebo-controlled clinical trial. Pain
in cancer patients. Cochrane Database Syst Rev (10):CD004311, 2013. 109:26, 2004.
29. Nicholson AB: Methadone for cancer pain. Cochrane Database Syst Rev 53. Johnson RW, Rice AS: Clinical practice. Postherpetic neuralgia. N Engl
(4):CD003971, 2007. J Med 371:1526, 2014.
30. Bruera E, Sweeney C: Methadone use in cancer patients with pain: A 54. Argoff CE: Review of current guidelines on the care of post herpetic
review. J Pall Med 5:127, 2002. neuralgia. Post grad Med 123:134, 2011.
31. Pani PP, et al: QTc interval screening for cardiac risk in methadone treat- 55. Watson CP, Vernich L, Chipman M, et al: Nortriptyline versus amitrip-
ment of opioid dependence. Cochrane Database Syst Rev (6):CD008939, tyline in postherpetic neuralgia: a randomized trial. Neurology 51:1166,
2013. 1998.
32. Santiago-Palma J, et al: Intravenous methadone in the management of 56. Wolff RF, Bala MM, Westwood M, et al: 5% lidocaine-medicated plaster
chronic cancer pain: safe and effective starting doses when substituting vs other relevant interventions and placebo for post herpetic neuralgia
methadone for fentanyl. Cancer 92(7):1919–1925, 2001. (PHN): a systemic review. Acta Neurol Scand 123:295, 2011.
33. Prommer E: Oxymorphone: a review. Support Care Cancer 14:109, 2006. 57. Edelsberg JS, Lord C, Oster G: Systemic review and meta-analysis of
34. Gabrail NY, Dvergsten C, Ahdieh H: Establishing the dosage equivalency efficacy, safety and tolerability data from randomized controlled trials of
of oxymorphone extended release and oxycodone controlled release in drugs used to treat postherpetic neuralgia. Ann Pharmacother 45:1483,
patients with cancer pain: A randomized controlled study. Curr Med Res 2011.
Opin 20:911, 2004. 58. Apalla Z, Sotiriou E, Lallas A, et al: Botulinum toxin A in postherpetic
35. Davis MP: Twelve reasons for considering buprenorphine as a frontline neuralgia: A parallel, randomized, double-blind, single-dose, placebo-
analgesic in the management of pain. J Support Oncol 10(6):209–219, controlled trial. Clin J Pain 29:857, 2013.
2012. 59. Kotani N, Kushikata T, Hashimoto H, et al: Intrathecal methylpred-
36. Schmidt-Hansen M, et al: Buprenorphine for treating cancer pain. nisolone for intractable postherpetic neuralgia. N Engl J Med 343:1514,
Cochrane Database Syst Rev (3):CD009596, 2015. 2000.
37. Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough 60. Ballas SK: Pain management of sickle cell disease. Hematol Oncol Clin
pain in cancer patients. Cochrane Database Syst Rev (1):CD004311, North Am 19:785, 2005.
2006. 61. Nelson L, et al: Curbing the opioid epidemic in the United States: the
38. Smith TJ, et al: Use of an implantable drug delivery system for refractory risk evaluation and mitigation strategy (REMS). JAMA 308(5):457–458,
chronic sickle cell pain. Am J Hematol 78(2):153–154, 2005. 2012.